The Impact of ROS and NGF in the Gliomagenesis and their Emerging Implications in the Glioma Treatment
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Reactive oxygen species (ROS) are highly reactive molecules derived from molecular oxygen (O2). ROS sources can be endogenous, such as cellular organelles and inflammatory cells, or exogenous, such as ionizing radiation, alcohol, food, tobacco, chemotherapeutical agents and infectious agents. Oxidative stress results in damage of several cellular structures (lipids, proteins, lipoproteins, and DNA) and is implicated in various disease states such as atherosclerosis, diabetes, cancer, neurodegeneration, and aging. A large body of studies showed that ROS plays an important role in carcinogenesis. Indeed, increased production of ROS causes accumulation in DNA damage leading to tumorigenesis. Various investigations demonstrated the involvement of ROS in gliomagenesis. The most common type of primary intracranial tumor in adults is represented by glioma. Furthermore, there is growing attention on the role of the Nerve Growth Factor (NGF) in brain tumor pathogenesis. NGF is a growth factor belonging to the family of neurotrophins. It is involved in neuronal differentiation, proliferation and survival. Studies were conducted to investigate NGF pathogenesis's role as a pro- or anti-tumoral factor in brain tumors. It has been observed that NGF can induce both differentiation and proliferation in cells. The involvement of NGF in the pathogenesis of brain tumors leads to the hypothesis of a possible implication of NGF in new therapeutic strategies. Recent studies have focused on the role of neurotrophin receptors as potential targets in glioma therapy. This review provides an updated overview of the role of ROS and NGF in gliomagenesis and their emerging role in glioma treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
CNS & neurological disorders drug targets - 23(2024), 4 vom: 18., Seite 449-462 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fanfarillo, Francesca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9061-61-4 |
|---|
| Anmerkungen: |
Date Completed 30.01.2024 Date Revised 19.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871527322666230403105438 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355212633 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355212633 | ||
| 003 | DE-627 | ||
| 005 | 20240419232025.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871527322666230403105438 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1380.xml |
| 035 | |a (DE-627)NLM355212633 | ||
| 035 | |a (NLM)37016521 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fanfarillo, Francesca |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Impact of ROS and NGF in the Gliomagenesis and their Emerging Implications in the Glioma Treatment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.01.2024 | ||
| 500 | |a Date Revised 19.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Reactive oxygen species (ROS) are highly reactive molecules derived from molecular oxygen (O2). ROS sources can be endogenous, such as cellular organelles and inflammatory cells, or exogenous, such as ionizing radiation, alcohol, food, tobacco, chemotherapeutical agents and infectious agents. Oxidative stress results in damage of several cellular structures (lipids, proteins, lipoproteins, and DNA) and is implicated in various disease states such as atherosclerosis, diabetes, cancer, neurodegeneration, and aging. A large body of studies showed that ROS plays an important role in carcinogenesis. Indeed, increased production of ROS causes accumulation in DNA damage leading to tumorigenesis. Various investigations demonstrated the involvement of ROS in gliomagenesis. The most common type of primary intracranial tumor in adults is represented by glioma. Furthermore, there is growing attention on the role of the Nerve Growth Factor (NGF) in brain tumor pathogenesis. NGF is a growth factor belonging to the family of neurotrophins. It is involved in neuronal differentiation, proliferation and survival. Studies were conducted to investigate NGF pathogenesis's role as a pro- or anti-tumoral factor in brain tumors. It has been observed that NGF can induce both differentiation and proliferation in cells. The involvement of NGF in the pathogenesis of brain tumors leads to the hypothesis of a possible implication of NGF in new therapeutic strategies. Recent studies have focused on the role of neurotrophin receptors as potential targets in glioma therapy. This review provides an updated overview of the role of ROS and NGF in gliomagenesis and their emerging role in glioma treatment | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Brain cancer | |
| 650 | 4 | |a NGF | |
| 650 | 4 | |a ROS | |
| 650 | 4 | |a carcinogenesis | |
| 650 | 4 | |a glioma | |
| 650 | 4 | |a gliomagenesis. | |
| 650 | 4 | |a oxidative stress | |
| 650 | 7 | |a Nerve Growth Factor |2 NLM | |
| 650 | 7 | |a 9061-61-4 |2 NLM | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 650 | 7 | |a Receptors, Nerve Growth Factor |2 NLM | |
| 700 | 1 | |a Ferraguti, Giampiero |e verfasserin |4 aut | |
| 700 | 1 | |a Lucarelli, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Francati, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Barbato, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Minni, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccanti, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Tarani, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Petrella, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Fiore, Marco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS & neurological disorders drug targets |d 2006 |g 23(2024), 4 vom: 18., Seite 449-462 |w (DE-627)NLM161975518 |x 1996-3181 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g number:4 |g day:18 |g pages:449-462 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871527322666230403105438 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |e 4 |b 18 |h 449-462 | ||